Literature DB >> 23744183

Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.

Cagatay Karaca1, Ayse Ozturk Oner, Ertugrul Mirza, Osman Ahmet Polat, Mustafa Sahiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23744183     DOI： 10.1001/jamaophthalmol.2013.400

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  9 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Intravitreal injection of bevacizumab for retinopathy of prematurity.

Authors:  Kazuki Kuniyoshi; Koji Sugioka; Hiroyuki Sakuramoto; Shunji Kusaka; Norihisa Wada; Yoshikazu Shimomura
Journal:  Jpn J Ophthalmol       Date:  2014-02-26       Impact factor: 2.447

3.  Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.

Authors:  Joel Hanhart; Doron S Comaneshter; Yossi Freier-Dror; Shlomo Vinker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-10       Impact factor: 3.117

4.  Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP).

Authors:  Ayad Shafiq; Roxane Hillier; Richard Hearn
Journal:  BMJ Case Rep       Date:  2020-03-12

Review 5.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

6.  Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy.

Authors:  Leonid Zlotcavitch; Harry W Flynn; Robert L Avery; Aleksandra Rachitskaya
Journal:  Clin Ophthalmol       Date:  2015-01-06

7.  Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy.

Authors:  Jeffrey J Tan; Charles L Cai; Eric M Shrier; Lois McNally; Douglas R Lazzaro; Jacob V Aranda; Kay D Beharry
Journal:  J Ophthalmol       Date:  2017-07-09       Impact factor: 1.909

8.  Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors.

Authors:  Fatemeh Bazvand; Hamid Riazi-Esfahani; Ahmad Mirshahi; Alireza Khodabande; Hasan Khojastheh; Afsar Dastjani Farahani; Ramak Roohipourmoallai; Marjan Imani; Hooshang Faghihi; Nazanin Ebrahimi Adib; Mohammadreza Mehrabi Bahar
Journal:  Int J Retina Vitreous       Date:  2021-01-11

Review 9.  What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

Authors:  Robert L Avery
Journal:  Br J Ophthalmol       Date:  2013-12-10       Impact factor: 4.638
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.